13F Holdings
中文EN

SPRB SPRUCE BIOSCIENCES, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1683553 · Fiscal year ends 12/31

Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-90.2%
TTM net income YoY-21.4%
TTM EPS YoY-55.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-7,100.0%
Net margin-6,869.3%
FCF margin-6,821.8%
EBITDA margin-7,096.4%

Returns

ROE-167.9%
ROA-119.1%
ROIC (approx.)—
Asset turnover0.02x

Leverage & solvency

Liabilities / assets64.8%
Debt / equity0.10x
Current ratio1.54x
Interest coverage-353.48x

Cash quality & payout

Operating cash flow / net income0.99x
Accruals ratio-0.8%
Payout ratio—
Capex / revenue0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$0$4.91M$10.09M$0—
R&D expense$19.52M$46.42M$49.43M$35.20M$30.70M
SG&A expense$16.99M$14.64M$12.65M$12.09M$11.37M
Operating income-$36.51M-$56.15M-$51.99M-$47.28M-$42.07M
Interest expense$90,000$307,000$483,000$420,000$345,000
Income tax$0$0$0$0$0
Net income-$38.97M-$53.04M-$47.92M-$46.18M-$42.29M
EBITDA-$36.49M-$56.10M-$51.92M-$47.21M-$42.00M
EPS (basic)-50.83-96.40-1.24-1.96-1.81
EPS (diluted)-50.83-96.40-1.24-1.96-1.81
Weighted avg. shares (diluted)766,598550,14638.51M23.53M23.36M
Balance sheet
Cash & equivalents$48.91M$38.79M$96.37M$24.73M$42.96M
Short-term investments——$0$54.59M$46.22M
Receivables———$0—
Current assets$52.11M$44.21M$102.18M$83.61M$91.89M
PP&E, net————$140,000
Total assets$53.02M$45.21M$103.95M$85.65M$126.49M
Current liabilities$10.09M$15.25M$24.46M$12.45M$8.87M
Short-term debt$0$1.62M$1.62M$1.62M$0
Long-term debt$0$124,000$1.72M$3.29M$4.88M
Total debt$0$1.75M$3.34M$4.92M$4.88M
Total liabilities$10.51M$16.39M$27.44M$17.16M$15.12M
Shareholders' equity$42.52M$28.82M$76.51M$68.49M$111.37M
Net debt-$48.91M-$37.04M-$93.03M-$19.82M-$38.09M
Shares outstanding1.37M563,04241.03M23.60M23.49M
Cash flow statement
Operating cash flow-$33.33M-$55.96M-$33.27M-$41.68M-$35.88M
Capital expenditure—$0$7,000$8,000$93,000
Free cash flow—-$55.96M-$33.28M-$41.69M-$35.97M
Investing cash flow—$0$55.78M$23.69M-$79.17M
Financing cash flow$43.48M-$1.62M$49.14M-$241,000$643,000
Depreciation & amortization$21,000$46,000$70,000$74,000$68,000
Stock-based compensation$2.57M$5.35M$4.62M$3.63M$3.96M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.